New: OncopeptTUME = Access to the tumor microenvironment utilizing NGS data
New: OncopeptVAC = Delivers prioritized T-cell neo-epitopes, that can be used as a vaccine
Cancer immunotherapy works only when:
- Tumor cells are recognized as foreign by the host immune system
- Cytotoxic T-cells are activated
Neo-Antigens
Mutations that activate T-cell immune responses
Neo-Epitopes
Mutations that are recognized by the immune system.
Why are T-cell neo-epitopes important?
- Predict efficacy of cancer immunotherapy drugs
- Enable patient selection
- Predict patient outcome
OncoPept platform integrates robust molecular profiling capabilities, combined with accurate data analysis to generate insights for better selection of T-cell neo-epitopes.
1. Molecular Profiling
Exome sequencing RNA sequencing
2. Data Analysis
Somatic mutation calling Expression level of mutant genes HLA typing
3. T-cell neo-epitope discovery
Generating a library of wild-type and mutant peptides HLA binding (multiple algorithms) Motif analysis Peptide processing
T-cell neo-epitopes from a Head & Neck cancer sample
OncoPept uses multiple filters to eliminate greater than 99% of neo-antigens to select true T-cell neo-epitopes
How can the solution help?
